Belluscura (BELL) Competitors GBX 0.75 0.00 (0.00%) As of 07/31/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock BELL vs. RUA, MHC, SUN, MXCT, DEMG, NIOX, SN, EKF, CREO, and IUGShould you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), MaxCyte (MXCT), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical devices" industry. Belluscura vs. Its Competitors RUA Life Sciences MyHealthChecked Surgical Innovations Group MaxCyte Deltex Medical Group NIOX Group Smith & Nephew EKF Diagnostics Creo Medical Group Intelligent Ultrasound Group Belluscura (LON:BELL) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership. Is BELL or RUA more profitable? RUA Life Sciences has a net margin of -65.72% compared to Belluscura's net margin of -1,030.73%. RUA Life Sciences' return on equity of -26.38% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets Belluscura-1,030.73% -102.62% -43.53% RUA Life Sciences -65.72%-26.38%-17.50% Does the media refer more to BELL or RUA? In the previous week, Belluscura's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score. Company Overall Sentiment Belluscura Neutral RUA Life Sciences Neutral Do insiders & institutionals hold more shares of BELL or RUA? 6.3% of Belluscura shares are held by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are held by institutional investors. 56.3% of Belluscura shares are held by company insiders. Comparatively, 51.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, BELL or RUA? RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelluscura£2.87M0.66-£29.55M-£9.37-0.08RUA Life Sciences£4.05M1.75-£2.66M-£4.29-2.67 Which has more risk & volatility, BELL or RUA? Belluscura has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. SummaryRUA Life Sciences beats Belluscura on 9 of the 11 factors compared between the two stocks. Get Belluscura News Delivered to You Automatically Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BELL vs. The Competition Export to ExcelMetricBelluscuraMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£1.89M£3.44B£5.53B£3.03BDividend YieldN/A2.44%4.74%5.02%P/E Ratio-0.0878.8219.28176.75Price / Sales0.66101.43440.87264,362.45Price / Cash8.0015.9935.0727.97Price / Book0.063.938.254.53Net Income-£29.55M£132.05M£3.25B£5.90B7 Day PerformanceN/A-3.03%-3.73%12.58%1 Month PerformanceN/A3.22%4.28%6.10%1 Year Performance-93.75%8.11%25.85%71.60% Belluscura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BELLBelluscuraN/AGBX 0.75flatN/AN/A£1.89M£2.87M-0.0824RUARUA Life SciencesN/AGBX 11.25-4.3%N/A+7.1%£6.98M£4.05M-2.6248Gap DownMHCMyHealthCheckedN/AGBX 12.33+0.7%N/A+25.4%£6.42M£9.43M-6.1516Gap DownSUNSurgical Innovations GroupN/AGBX 0.66-6.3%N/A-3.1%£6.12M£12.54M-21.1180Gap DownMXCTMaxCyteN/AGBX 2.25-0.9%N/A-99.4%£2.97M£57.52M-0.0880High Trading VolumeDEMGDeltex Medical GroupN/AN/AN/AN/A£187K£1.76M-0.1537Gap UpHigh Trading VolumeNIOXNIOX Group2.6076 of 5 starsGBX 70.50+0.4%GBX 90+27.7%+11.1%£28.96B£3.53B2,909.4992News CoverageHigh Trading VolumeSNSmith & Nephew3.1185 of 5 starsGBX 1,180+0.8%GBX 7,840+564.4%+5.1%£12.94B£7.08B42.4818,452News CoverageHigh Trading VolumeEKFEKF DiagnosticsN/AGBX 29.91-3.5%N/A+12.6%£132.95M£49.91M27.84356News CoverageGap DownCREOCreo Medical GroupN/AGBX 13.50+1.9%N/A-58.9%£54.58M£33.87M-2.14279IUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165 Related Companies and Tools Related Companies RUA Competitors MHC Competitors SUN Competitors MXCT Competitors DEMG Competitors NIOX Competitors SN Competitors EKF Competitors CREO Competitors IUG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BELL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belluscura plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belluscura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
